Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Correction: Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography.

Löbel U, Forkert ND, Schmitt P, Dohrmann T, Schroeder M, Magnus T, Kluge S, Weiler-Normann C, Bi X, Fiehler J, Sedlacik J.

PLoS One. 2017 Feb 14;12(2):e0172450. doi: 10.1371/journal.pone.0172450. eCollection 2017.

2.

Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography.

Löbel U, Forkert ND, Schmitt P, Dohrmann T, Schroeder M, Magnus T, Kluge S, Weiler-Normann C, Bi X, Fiehler J, Sedlacik J.

PLoS One. 2016 Nov 1;11(11):e0164863. doi: 10.1371/journal.pone.0164863. eCollection 2016. Erratum in: PLoS One. 2017 Feb 14;12 (2):e0172450.

3.

ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer.

Hofmann BT, Stehr A, Dohrmann T, Güngör C, Herich L, Hiller J, Harder S, Ewald F, Gebauer F, Tachezy M, Precht C, Izbicki JR, Bockhorn M, Wagener C, Wolters-Eisfeld G.

Clin Cancer Res. 2014 Dec 1;20(23):6117-26. doi: 10.1158/1078-0432.CCR-14-0716. Epub 2014 Oct 15.

4.

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

Drenckhan A, Grob T, Dupree A, Dohrmann T, Mann O, Izbicki JR, Gros SJ.

Langenbecks Arch Surg. 2014 Oct;399(7):879-88. doi: 10.1007/s00423-014-1235-1. Epub 2014 Jul 29.

PMID:
25070024
5.

Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.

Dohrmann T, Kutup A, Mahner S, Müller V, Jaenicke F, Izbicki JR, Vashist YK.

J Clin Oncol. 2013 Apr 20;31(12):e208-10. doi: 10.1200/JCO.2012.45.1708. Epub 2013 Mar 18. No abstract available.

PMID:
23509305
6.

The T393C polymorphism of GNAS1 is a predictor for relapse and survival in resectable non-small cell lung cancer.

Uzunoglu FG, Heumann A, Musici S, Kutup A, Koenig A, Roch N, Thomssen A, Dohrmann T, Tsui TY, Mann O, Izbicki JR, Vashist YK.

Lung Cancer. 2013 Feb;79(2):151-5. doi: 10.1016/j.lungcan.2012.11.003. Epub 2012 Nov 29.

PMID:
23201296
7.

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer.

Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, Reichelt U, Kaifi JT, Izbicki JR, Gros SJ.

J Surg Res. 2013 Jun 15;182(2):250-6. doi: 10.1016/j.jss.2012.09.035. Epub 2012 Oct 10.

PMID:
23117118
8.

Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Gros SJ, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Effenberger K, Reichelt U, Hoffman RM, Pantel K, Kaifi JT, Izbicki JR.

PLoS One. 2012;7(10):e47287. doi: 10.1371/journal.pone.0047287. Epub 2012 Oct 17. Erratum in: PLoS One. 2013;8(5). doi: 10.1371/annotation/5dafa9a8-2e6d-4487-b35f-7126141fe00e.

9.

Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer.

Gros SJ, Dohrmann T, Rawnaq T, Kurschat N, Bouvet M, Wessels J, Hoffmann RM, Izbicki JR, Kaifi JT.

Anticancer Res. 2010 Oct;30(10):3933-8.

PMID:
21036705
10.

Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma.

Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, Peldschus K, Adam G, Hoffman RM, Izbicki JR, Kaifi JT.

Mol Cancer Ther. 2010 Jul;9(7):2037-45. doi: 10.1158/1535-7163.MCT-10-0209. Epub 2010 Jul 6.

11.

Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model.

Gros SJ, Dohrmann T, Peldschus K, Schurr PG, Kaifi JT, Kalinina T, Reichelt U, Mann O, Strate TG, Adam G, Hoffman RM, Izbicki JR.

Int J Cancer. 2010 Jun 1;126(11):2671-81. doi: 10.1002/ijc.24980.

Supplemental Content

Loading ...
Support Center